As previous studies from our laboratory showed AB680 reduces the growth of KPC tumors (20) when tumors were treated starting early in tumor development, in this work we evaluated in our preclinical syngeneic PDA model an in vivo CD73 inhibition with AB680 in combination with RFA and observed a more significant decrease in tumor growth when AB680 is used in combination with RFA. Here, NT5E is linked to neoplasm.